Lifevantage Corp. Files 8-K on Shareholder Votes

TL;DR

LFVN filed an 8-K on Nov 7th regarding shareholder votes. Expect updates on corporate actions.

AI Summary

Lifevantage Corp. filed an 8-K on November 14, 2024, reporting on matters submitted to a vote of security holders as of November 7, 2024. The filing details the company's corporate structure and historical name changes, including its former names Lifeline Therapeutics, Inc., Yaak River Resources Inc., and Andraplex Corp.

Why It Matters

This filing indicates that Lifevantage Corp. held a vote of its security holders, which could pertain to significant corporate decisions or governance matters.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not immediately indicate significant financial distress or operational changes.

Key Numbers

• 20241107 — Date of earliest event reported (This is the date the reported event (shareholder vote) occurred.)
• 20241114 — Filing Date (This is the date the 8-K was officially filed with the SEC.)

Key Players & Entities

• Lifevantage Corp. (company) — Registrant
• Lifeline Therapeutics, Inc. (company) — Former company name
• Yaak River Resources Inc (company) — Former company name
• Andraplex Corp (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ) of the Act: Common Stock, par value $0.0001 LFVN The Nasdaq Stock Market LLC Title

Filing Documents

• lfvn-20241107.htm (8-K) — 57KB
• 0000849146-24-000142.txt ( ) — 183KB
• lfvn-20241107.xsd (EX-101.SCH) — 2KB
• lfvn-20241107_lab.xml (EX-101.LAB) — 22KB
• lfvn-20241107_pre.xml (EX-101.PRE) — 13KB
• lfvn-20241107_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. LifeVantage Corporation (the "Company") held its fiscal year 2025 annual meeting of stockholders on November 7, 2024 (the "Annual Meeting"). Of the 12,484,004 shares of the Company's common stock outstanding as of the record date, 8,790,929 shares, or 70.4% were represented at the Annual Meeting either in person or by proxy. The following proposals were submitted to a vote of the Company's stockholders at the Annual Meeting: 1. To elect the following eight director nominees to the Company's board of directors to hold office until the Company's fiscal year 2026 annual meeting of stockholders or until their respective successors are elected and qualified: Mr. Rajendran Anbalagan Mr. Dayton Judd Mr. Michael A. Beindorff Ms. Cynthia Latham Mr. Steven R. Fife Mr. Darwin K. Lewis Mr. Raymond B. Greer Mr. Garry Mauro 2. To approve, on an advisory basis, a resolution approving the compensation of the Company's named executive officers; 3. To ratify the selection of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending June 30, 2025; 4. To approve an amendment to the 2017 Long-Term Incentive Plan; 5. To approve an amendment to the 2019 Employee Stock Purchase Plan; and 6. To approve, on an advisory basis, a resolution approving the frequency of future stockholder advisory votes on the compensation of the Company's named executive officers of one, two or three years. The proposals submitted to a vote of the Company's stockholders at the Annual Meeting are more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on September 20, 2024. The final voting results of each proposal were as follows: Proposal 1 – Election of Directors . The Company's stockholders elected each of the eight director nominees listed above to the Company's board of directors (the "Board") t

View Full Filing

View this 8-K filing on SEC EDGAR